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ARTICLE
Predicted Effects of Missense Mutations on Native-State Stability
Account for Phenotypic Outcome in Phenylketonuria, a Paradigm
of Misfolding Diseases
Angel L. Pey, Franc¸ois Stricher, Luis Serrano, and Aurora Martinez
Phenylketonuria (PKU) is a genetic disease caused by mutations in human phenylalanine hydroxylase (PAH). Most
missense mutations result in misfolding of PAH, increased protein turnover, and a loss of enzymatic function. We studied
the prediction of the energetic impact on PAH native-state stability of 318 PKU-associated missense mutations, using
the protein-design algorithm FoldX. For the 80 mutations for which expression analyses have been performed in eukaryote
systems, in most cases we found substantial overall correlations between the mutational energetic impact and both in
vitro residual activities and patient metabolic phenotype. This finding confirmed that the decrease in protein stability
is the main molecular pathogenic mechanism in PKU and the determinant for phenotypic outcome. Metabolicphenotypes
have been shown to be better predicted than in vitro residual activities, probably because of greater stringency in the
phenotyping process. Finally, all the remaining 238 PKU missense mutations compiled at the PAH locus knowledgebase
(PAHdb) were analyzed, and their phenotypic outcomes were predicted on the basis of the energetic impact provided
by FoldX. Residues in exons 7–9 and in interdomain regions within the subunit appear to play an important structural
role and constitute hotspots for destabilization. FoldX analysis will be useful for predicting the phenotype associated
with rare or new mutations detected in patients with PKU. However, additional factors must be considered that may
contribute to the patient phenotype, such as possible effects on catalysis and interindividual differences in physiological
and metabolic processes.
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Phenylketonuria (PKU [MIM 261600]) is a human meta-
bolic disease caused by mutations in the phenylalanine
hydroxylase gene (PAH) and is inherited in an autosomal
recessive Mendelian fashion. Phenylalanine hydroxylase
(PAH, also known as “phenylalanine 4-monooxygenase”
[EC 1.14.16.1]) catalyzes the rate-limiting step in L-phe-
nylalanine (L-Phe) catabolism in liver, using tetrahydro-
biopterin (BH4) and dioxygen as additional cosubstrates.
PKU mutations are associated with impairment of PAH
activity, leading to accumulation of L-Phe in plasma—that
is, hyperphenylalaninemia (HPA)—and neurological dam-
age in untreated patients.1,2 Two parameters have tradi-
tionally been used to classify patients with PKU into dif-
ferent phenotypic groups: plasma L-Phe levels (under
normal feeding conditions) and daily L-Phe tolerance
(with L-Phe levels kept within therapeutic ranges). The
main determinant of the metabolic phenotype in patients
with PKU is the mutant genotype, although the fact that
1500 mutations in the PAH gene have been reported makes
PKU a highly heterogeneous disease from both genetic and
metabolic perspectives.3,4 About two-thirds of PKU mu-
tations are missense, causing single amino acid changes
in the PAH sequence. The effects of ∼100 of these muta-
tions on PAH function and stability have been identified
by means of in vitro expression analysis (extensively com-
piled in the PAH locus knowledgebase [PAHdb]).5 The pre-
dominant molecular mechanism in PKU appears to be a
loss-of-function pathogenesis due to decreased stability
and/or folding efficiency in the PAH protein with mu-
tation.4,6–9 Thus, a large proportion of all missense muta-
tions studied, including many of the most common mu-
tations found in patients, display stability and folding
defects when they are expressed in vitro.4,8–10 These variant
PAH proteins are found to aggregate when expressed in
prokaryote systems, where they appear as both soluble and
insoluble aggregates.6–9 But the presence of amyloid fibrils
or insoluble aggregates has not been reported in the liver
of PKU-affected individuals, and PKU has, in fact, been
classified as a cytosol-associated protein-misfolding dis-
ease.11 The current understanding of PKU is, thus, that the
PAH mutant proteins are degraded in vivo more rapidly
than wild-type (WT) protein by the proteasome or other
protein quality-control proteolytic systems in hepato-
cytes.4,10,12 A loss-of-function mechanism associated with
increased degradation rather than aggregation of the mu-
tants has also been reported as the molecular basis of other
important genetic diseases, such as cystic fibrosis, Fabry
disease, hypogonadotrophic hypogonadism, and familiar
hypercholesterolemia.13,14
For many PKU mutations, a correlation between ge-
notype (mutant alleles) and in vivo metabolic phenotype
(plasma L-Phe and L-Phe tolerance) in patients and in vi-
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tro–expressed mutant residual activity can be semiquan-
titatively established (for studies including large sets of
mutations, see the work of Gjetting et al.8 and Pey et al.9;
for a recent and very comprehensive review, see the work
of Gu¨ttler3). The absence of a quantitative relationship
between in vivo phenotypes and in vitro residual activity
seems to be related to the use of different cellular model
systems (eukaryotic and prokaryotic), which may ex-
acerbate or attenuate folding and stability defects, because
of their different abilities to support folding.10 For some
other mutations, the inconsistencies reported are possibly
related to PKU misclassification, since there are no gen-
erally accepted international guidelines and because phe-
notypes are sensitive to age and BMI.3 Interindividual dif-
ferences in other metabolic and physiological processes,
such as intestinal absorption or transport of L-Phe, may
also contribute to inconsistencies in the genotype-phe-
notype correlations in PKU mutations.15
Several crystal structures of truncated forms of mam-
malian PAH16–19 have provided an experimental frame-
work to qualitatively explain the effects of many PKU
mutations on PAH activity and stability.20,21 Stability and
folding defects observed in in vitro expression analyses
have been rationalized in terms of altered interactions in
the native structure because of mutation,20–22 possibly
leading to reduced kinetic or thermodynamic stability.4,10
However, PAH displays a quite complex protein architec-
ture, organized as an asymmetric dimer of dimers, and
contains three functional domains per monomer.22 More-
over, the enzyme does not undergo reversible chemical
or thermal denaturation, which is a prerequisite for the
quantitative study and comparison of the thermodynamic
stability of WT and mutant proteins. For this reason, it
has been assumed that the lowered solubility or “opera-
tional” thermal stability in vitro (see, e.g., the work of
Ga´mez et al.7 and Pey et al.9) reflects reduced thermody-
namic stability.4,10 Nevertheless, to date, no attempt has
been made to quantitatively correlate mutational effects
on PAH stability with in vitro residual activity or phe-
notypic outcome in patients.
In this article, we evaluate the energetic impact of all
missense PKU mutations ( ) identified to date onNp 318
PAH native-state stability, by using the available crystal
structures and structural models for the human PAH pro-
tein. The energetic penalties were evaluated using the new
FoldX energy function.23 Changes in PAH stability as a
result of mutation (in terms of DDG values) were then
compared with both the residual activities determined in
vitro in eukaryotic expression systems and the patient
phenotypes associated with these mutations in the avail-
able literature. This is the first large-scale study, to our
knowledge, to demonstrate relatively good mutation-
based prediction of disease outcome. We were able to con-
firm and quantify changes in protein stability as the main
molecular pathogenic mechanisms in PKU, except in a few
mutations that are mostly catalytic. Our results help to
identify the amino acids and regions with the greatest
effects on the stability of the protein and represent a tool
potentially capable of assisting individual patients on the
basis of the outcome predicted by FoldX.
Data and Methods
PAH Structural Models
Human and rat PAH show 90% sequence identity. The humanized
versions of the crystal structures of dimeric rat PAH (residues 19–
427) in the phosphorylated (Protein Data Bank [PDB] 1PHZ) and
nonphosphorylated (PDB 2PHM) forms were prepared by chang-
ing the residues that differ between rat and human PAH and then
regularizing the structure with use of the BuildModel option of
FoldX in the new version, 2.65. Energy calculations show com-
patibility of the human variations with the rat structure. Cal-
culations were also performed on the N-terminal truncated tet-
rameric human PAH, residues 111–452 (PDB 2PAH). Moreover,
calculations were attempted on a composite model of the full-
length human tetrameric structure.24 However, this model, al-
though apparently correct, contains numerous van der Waals
clashes that could not be resolved, even after various runs of
minimization and molecular-dynamics simulations. This was not
the case for the humanized dimeric rat structures that could be
modeled without any problem.
FoldX Force Field
The FoldX energy function includes terms that have been found
to be important for protein stability. The free energy from the
unfolding (DG) of a target protein is calculated using equation
(1):
DGpW #DG W #DG (1)vdw vdw solvH solvH
W #DG DGsolvP solvP wb
DG DG DGhbond el Kon
W #T#DS W #Tmc mc sc
#DS W #DG ,sc clash clash
where DGvdw is the sum of the van der Waals contributions of all
atoms with respect to the same interactions with the solvent.
DGsolvH and DGsolvP are the differences in solvation energy for apo-
lar and polar groups, respectively, when these groups change from
the unfolded to the folded state. DGhbond is the free-energy dif-
ference between the formation of an intramolecular hydrogen
bond and the formation of an intermolecular hydrogen bond
(with solvent). DGwb is the extra stabilizing free energy provided
by a water molecule that makes more than one hydrogen bond
to the protein (water bridges) and that cannot be taken into ac-
count with nonexplicit solvent approximations.25 DGel is the elec-
trostatic contribution of charged groups, including the helix di-
pole. DSmc is the entropy cost of fixing the backbone in the folded
state; this term is dependent on the intrinsic tendency of a par-
ticular amino acid to adopt certain dihedral angles.26 Finally, DSsc
is the entropic cost of fixing a side chain in a particular confor-
mation,27 and the DGclash term provides a measure of the steric
overlaps between atoms in the structure.
When we are working with oligomeric proteins or protein com-
plexes, two extra terms are involved: DGkon, which reflects the
effect of electrostatic interactions on the association constant kon
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Table 1. Classification of 80 PKU
Mutations into Three Types (I–III),
Depending on Their Residual In Vitro
Activities
Type and
Mutanta
Residual Activityb
(%)
Ic ( ):np 19
R53H 79
D59Y 92
R68G 100
R68S (3) 5736
P69S 69
E76G 85
T92I 76
D143G (2) 68
P211T 72
G218V (3) 6435
V230I 63
P244L (2) 51
V245A 50
R261Q (6) 5126
K274E 100
A322G 75
E390G 75
A403V (2) 66
D415N 72
IId ( ):np 33
L41F 10
K42I 12
G46S (2) 16
A47V 12.5
L48S 39
L52S 27
I65T (5) 4133
S70P 20
S87R 25
G103S 39
A104D (2) 27
P122Q 22
T124I 42
R158Q (3) 1611
G171A 27
I174T 12
R176L 42
E178V 18
R241C 25
R241H 23
R243Q (3) 135
I283F 10
L293M 41
I306V 39
A309V (2) 40
A342T 26
L348V (4) 358
V388M (4) 2816
A395P 16
R408Q (3) 4643
R413S 32
R413P 3545
Y414C 4226
IIIe ( ):np 28
R157N 5
F161S 7
W187C 1
V245L 7
V245E 7
(continued)
Table 1. (continued)
Type and
Mutanta
Residual Activityb
(%)
G247V 4
R252W (2) 0
R252Q (2) 2.5
R252G (2) 3.0
L255V (2) 7.0
L255S (2) 2.0
A259T (2) 5.5
A259V (3) 2.01.7
R270S (3) 1.71.5
Y277D 0
T278I 1
E280K (4) 2.22.6
P281L (3) 2.33.2
D282N 2
F299C 3
L311P (2) .5
G332V 0
L333F 7
S349P (3) .5.4
S349L (2) 0
S391I 0
R408W (4) 1.21.1
A447P 8
a In parentheses after the mutant, the num-
ber of reported measurements (if more than one)
used for the mean in vitro residual activity es-
timation is given (data from PAHdb; references
for the individual expression and activity studies
are available from PAHdb, and additional data
are reported elsewhere30,31).
b Given as % of WT activity obtained in each
study. SDs are given for some mutations for
which more than one report is available.
c Type I mutant activity is 50% of WT ac-
tivity (meanSD 71.8%14.9%).
d Type II mutant activity is 10%–50% of WT
activity (meanSD 27.2%11.4%).
e Type III mutant activity is !10% of WT ac-
tivity (meanSD 2.9%2.6%).
(this applies only to the subunit binding energies),28 and DStr,
which is the loss of translational and rotational entropy that
ensues after formation of the complex. The latter term cancels
out when we are looking at the effect of point mutations on
complexes.
The energy values of DGvdw, DGsolvH, DGsolvP, and DGhbond attrib-
uted to each atom type have been derived from a set of experi-
mental data, and DSmc and DSsc have been taken from theoretical
estimates. The terms Wvdw, WsolvH, WsolvP, Wmc, and Wsc correspond
to the weighting factors applied to the raw energy terms. They
are all 1, except for the van der Waals contribution (Wvdw), which
is 0.33 (the van der Waals contributions are derived from vapor-
to-water energy transfer, whereas, in the protein, we are going
from solvent to protein). For a detailed explanation of the FoldX
force field, see the work of Schymkowitz et al.23,29 and the FoldX
Web server.
FoldX Modeling
To model the mutations on the humanized structures, we used
the BuildModel option of FoldX, version 2.65. This command
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reads the PDB and duplicates it internally. Then, it mutates the
selected position in one molecule to itself and, in the other, to
the variant selected, while moving the neighboring side chains.
We ensure that the moving side chains and the rotamer set for
them are the same in both cases. In this way, we prevent arte-
factual changes in energy due to the release, for example, of a
clash in a neighboring side chain in the mutant. The effect of
the mutation is then computed by subtracting the energy of the
self-mutated WT from that of the mutant. When working with
a dimer or tetramer, all mutations and self-mutations are per-
formed at the same time. The DDG values are provided in kilo-
calories per mole of dimer for all model structures.
Residual Activities of the Mutant Forms: “In Vitro”
Phenotype
To the best of our knowledge, 96 PAH mutant alleles have been
expressed to date in vitro in at least one expression system (com-
piled in PAHdb and references therein5,30,31), and all were evalu-
ated for inclusion in this study. Nine of these mutations were not
included for further classification and analysis because they are
known or expected to affect protein sequence beyond a single
amino acid substitution20,21,32: M1V (affecting mRNA translation),
F39del and I94del (amino acid deletions), [T63P;H64N] (double
mutant), EX6-96ArG (aberrant splicing/deletion), IVS10-11GrA
(aberrant splicing/inframe insertion), R243X and G272X (trun-
cations), and IVS121GrA (aberrant splicing/truncation). It is
worth noting that some additional mutations initially classified
as missense (or silent) can mask splicing defects.33,34 These effects
are not considered further in our analysis, since they must be
assessed experimentally. Of the remaining 87 mutant alleles, 7
were discarded because no expression analyses have been re-
ported in eukaryotic systems (E178G, S231P, R270K, A300S,
A313T, I318T, and A373T). We thus used a set of 80 mutations
(table 1) that have been expressed at least once in a eukaryotic
expression system (mammalian transfected cells or cell-free sys-
tems based on reticulocyte extracts [TnT systems]) and whose
activity measurements have been reported. These mutations are
distributed all over the PAH structure, include 31 of the 36 most
frequent missense mutations reported in patients (92.1% of re-
ported alleles), and represent 147.5% of the total mutant alleles
reported so far. The mutations were classified into three groups
(types I–III) (see table 1) on the basis of the mean residual activity
(compared with WT activity in each study).
Results of residual protein and activity obtained from expres-
sion of mutants in Escherichia coli have not been included in the
study, since, in such systems, PAH is usually expressed and an-
alyzed as a fusion protein with another protein partner, and fold-
ing and/or stability defects are accompanied by protein aggre-
gation, an event that has not been demonstrated to be associated
with PKU pathogenesis.11,14
Mutation-Associated Disease Outcome: “In Vivo” Phenotype
Assignment of individual PAH mutations to particular metabolic
phenotypes (genotype-phenotype correlation) has classically
been performed by comparing phenotypes in large genotype-
phenotype correlation studies that have included patients with
a certain mutation in homozygosity and/or functional hemi-
zygosity.32,35 Homozygosity (homoallelic mutant genotype)
seems to be more predictive (∼90% of correlations are consistent)
but less frequent than functional heterozygosity (genotype where
the mutation under analysis is present in trans with a null mu-
tation), for which ∼70% of correlations are consistent.32 Muta-
tions are considered null when they “are known or predicted to
completely abolish PAH activity,”35(p.73) such as frameshift muta-
tions (e.g., F55fsdelT, K363fsdelG, and P407fsdelC), splice-defec-
tive mutations (e.g., IVS12nt1gra or IVS10nt11gra), and base
substitutions that introduce a premature stop codon (e.g., R111X,
R243X, and R261X). Mutations that have been repeatedly re-
ported to show null activity (!3%32), such as R252W, R408W,
P281L, S349L, and S349P (table 1), are also considered null. Those
mutations that may not completely impair correct mRNA splic-
ing35 or lead to low but detectable activity when expressed in
vitro (R158Q or R243Q) are not regarded as null mutations. Oc-
casionally, some studies also include phenotypes that are asso-
ciated with quite rare mutations, using compound heterozygotes
(patients carrying two nonnull mutant alleles) because of the lack
of information about these mutations in homozygosity or func-
tional hemizygosity.9,36
Two parameters are used to estimate the severity of metabolic
phenotypes in patients with PKU: plasma L-Phe concentrations
at the time of diagnosis (typically with a normal diet) and L-Phe
tolerance (with L-Phe levels kept within a therapeutic range), both
depending on age.3 Different phenotypic groups have been pro-
posed on the basis of these two parameters and have been fol-
lowed throughout the past 2 decades. The cutoff values used as
boundaries between groups differ from author to author, and
recommendations for classification vary among countries.3,32,35,37–
40 Nevertheless, three consensus phenotypic groups emerge, from
the mildest to the more severe phenotype: (i) mild, benign, or
non-PKU HPA (MHP), (ii) mild or atypical PKU, and (iii) severe
or classic PKU. In some reports, an additional group called “mod-
erate PKU” is also found at the boundary between mild and severe
PKU (see below and table 2).
Among the mutations in table 1, 16 mutants have not been
identified in the literature as being explicitly associated with a
particular phenotype in patients, whereas 18 have no clear as-
sociation with a phenotypic group (table 3). These are inconsis-
tently associated with a broad range of phenotypes, from mild
to severe, or are described as “unclassified.” We thus classified
the remaining 46 mutations into three patient phenotypic
groups (table 2). Group 1 (meanSD in vitro residual activity
53.0%25.8%; ) corresponds to the very mild phenotypenp 13
in patients (MHP). In this group, we put the unambiguously
MHP mutations found in table 2. Group 2 (meanSD in vitro
residual activity, 41.5%16%; ) corresponds to the mildnp 13
PKU phenotype, and it was formed by combining mild MHP (re-
ported as either “MHP” or “mild” in different reports), mild PKU
(reported as “mild”), and mild-moderate PKU (reported as either
“mild” or “moderate” in the literature) mutants. The in vitro
residual activities of the mutants in this group are actually quite
similar (46%21%, 40%17%, and 35%7% for the mild MHP
[ ], mild PKU [ ], and mild-moderate PKU [ ] mu-np 6 np 4 np 3
tants, respectively). Group 3 (mean in vitro residual activity
6.9%11.1%; ) corresponds to severe PKU and includesnp 20
the only moderate mutant (A309V), in addition to a large group
of mutations unambiguously reported as “severe.”
BH4-Responsive Mutations
BH4-responsive PKU refers to the disease in a subgroup of patients
with PKU who have a positive response (showing a reduction in
their L-Phe plasma levels) to the administration of pharmacolog-
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Table 2. Classification of 46 PKU Mutations into
Phenotypic Groups
Group, Classification,a
and Mutation References
Group 1, MHP:
MHP ( ):np 13
A47V Gjetting et al.,8 Kayaalp et al.32
D59Y Pey et al.,9 Desviat et al.36
E76G Pey et al.,9 Desviat et al.36
S87R Jennings et al.,21 Kayaalp et al.,32
Guldberg et al.35
T92I Jennings et al.,21 Kayaalp et al.32
R176L Gjetting et al.,8 Jennings et al.,21
Kayaalp et al.,32 Desviat et al.36
V230I Gu¨ttler,3 Gjetting et al.,8 Jennings
et al.,21 Desviat et al.36
R241C Jennings et al.21
V245A Gu¨ttler,3 Gjetting et al.,8 Jennings
et al.,21 Desviat et al.36
I306V Gjetting et al.,8 Jennings et al.,21
Desviat et al.36
A322G Desviat et al.36
R413S Jennings et al.21
D415N Gu¨ttler,3 Kayaalp et al.,32 Desviat
et al.36
Group 2, mild PKU:
MHP-mild PKU ( ):np 6
P122Q MHP-mild PKU in Pey et al.9; mild
PKU in Desviat et al.36
G171A MHP in Guldberg et al.35; mild
PKU in Kayaalp et al.32
E390G MHP in Gu¨ttler,3 Gjetting et al.,8
Desviat et al.36; mild PKU-MHP
in Kayaalp et al.32; mild PKU in
Aulehla-Scholz et al.41
A403V MHP in Gu¨ttler,3 Desviat et al.36;
MHP-mild PKU in Kayaalp et
al.32
R408Q MHP in Kayaalp et al.32; MHP-mild
PKU in Pey et al.9; mild PKU in
Gu¨ttler,3 Gjetting et al.,8 Des-
viat et al.36
Y414C MHP in Pey et al.9; mild PKU in
Gu¨ttler,3 Gjetting et al.,8 Jen-
nings et al.,21 Desviat et al.36
Mild PKU ( ):np 4
R68S Gu¨ttler,3 Jennings et al.,21 Desviat
et al.36
A104D Gu¨ttler,3 Gjetting et al.,8 Kayaalp
et al.,32 Desviat et al.36
R241H Jennings et al.21
P244L Pey et al.,9 Desviat et al.36
Mild-moderate PKU ( ):np 3
I65T Mild PKU in Pey et al.,9 Desviat
et al.42; moderate PKU in Gu¨t-
tler,3 Gjetting et al.,8 Jennings
et al.21
L348V Mild PKU in Desviat et al.36; mod-
erate PKU in Gu¨ttler,3 Gjetting
et al.,8 Jennings et al.,21 Au-
lehla-Scholz et al.41
V388M Mild PKU in Desviat et al.36; mod-
erate PKU in Gu¨ttler,3 Gjetting
et al.,8 Jennings et al.21
Group 3, severe PKU:
Moderate PKU ( ):np 1
(continued)
Table 2. (continued)
Group, Classification,a
and Mutation References
A309V Pey et al.,9 Desviat et al.42
Severe PKU ( ):np 19
I174T Jennings et al.21
P211T Kayaalp et al.32
V245L Gjetting et al.8
R252W Pey et al.,9 Jennings et al.,21 Ka-
yaalp et al.,32 Desviat et al.36
R252Q Jennings et al.,21 Kayaalp et al.,32
Guldberg et al.35
R252G Jennings et al.,21 Guldberg et
al.35
A259V Jennings et al.21
Y277D Pey et al.,9 Desviat et al.36
E280K Gjetting et al.,8 Kayaalp et al.,32
Desviat et al.36
P281L Gu¨ttler,3 Gjetting et al.,8 Kayaalp
et al.,32 Desviat et al.36
D282N Jennings et al.,21 Guldberg et
al.35
I283F Kayaalp et al.32
F299C Jennings et al.,21 Kayaalp et al.,32
Aulehla-Scholz et al.41
L311P Jennings et al.,21 Desviat et al.36
A342T Gjetting et al.,8 Jennings et al.21
S349P Gjetting et al.,8 Jennings et al.,21
Kayaalp et al.,32 Desviat et al.36
S349L De Lucca et al.43
A395P Gjetting et al.8
R408W Gjetting et al.,8 Pey et al.,9 Ka-
yaalp et al.,32 Desviat et al.36
a Classification according to plasma L-Phe levels and/or daily L-Phe
tolerance, typically measured after newborn screening or at age 5
years. The phenotypic groups are based on the reports cited, where
the cutoff values for plasma L-Phe levels or daily L-Phe tolerance vary
among reports and under different national guidelines.21,32,35,36,38,39,
42,44,45 MHP, also called “mild,” “benign,” or “non-PKU” HPA, with
plasma L-Phe !360–600 mM and very high L-Phe tolerance (11,000
mg/d). Patients typically display normal development in the absence
of L-Phe restriction and need only minor changes in dietary protein
intake. Mild PKU, also called “atypical” or “variant” PKU, with plasma
L-Phe in the 360–1,200 mM range and daily L-Phe tolerance of 400–
1,000 mg/d. If untreated, patients develop abnormally to different
degrees, and their intelligence quotient is significantly affected. Mod-
erate PKU, an intermediate group used by some authors to distinguish
between mild and severe phenotypes, with plasma L-Phe values of
900–1,800 mM and daily L-Phe tolerance of 350–500 mg/d. Severe
PKU, also called “classic” PKU, with plasma L-Phe levels 11,200–1,800
mM and daily L-Phe tolerance !250–400 mg/d. If untreated, the pa-
tient’s development rapidly and irreversibly deteriorates, leading to
severe mental retardation. See the “Mutation-Associated Disease Out-
come: “In Vivo Phenotype” subsection for further details about the
classification into groups.
ical doses of the natural cofactor BH4 and display a high degree
of heterogeneity at the genetic (mutational) level. Seventy-three
mutations have been found in patients with BH4-responsive PKU
(as compiled in the BIOPKU database). Of these mutations, 39
were not included in the FoldX analysis because of their effects
on splicing or truncation of PAH protein or their association with
patients with nonresponsive PKU.47 The remaining 34 mutations
are compiled in table 4. The main molecular mechanism under-
lying BH4 responsiveness appears to be a chaperone-like effect,
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Table 3. PKU Mutations Discarded
for Further Analysis because of Lack of Reported
or Inconsistent Phenotype Classification
Mutationa Reference(s)
L41F Guldberg et al.35
G46S Gjetting et al.,8 Jennings et al.,21 Kayaalp et al.,32
Guldberg et al.,35 Desviat et al.,36 Eiken et al.46
L48S Jennings et al.,21 Guldberg et al.,35 Desviat et al.,36
Aulehla-Scholz et al.41
D143G Jennings et al.21
R158Q Gjetting et al.,8 Jennings et al.,21 Kayaalp et al.,32
Guldberg et al.,35 Desviat et al.,36 Aulehla-Scholz
et al.41
F161S Jennings et al.21
E178V Jennings et al.21
G218V Gjetting et al.,8 Jennings et al.,21 Guldberg et al.35
R243Q Jennings et al.,21 Guldberg et al.,35 Desviat et al.36
V245E Gjetting et al.8
G247V Jennings et al.21
L255V Jennings et al.21
L255S Jennings et al.21
A259T Jennings et al.21
R261Q Gjetting et al.,8 Jennings et al.,21 Kayaalp et al.,32
Guldberg et al.,35 Aulehla-Scholz et al.,41 Desviat
et al.42
R270S Jennings et al.21
L333F Jennings et al.21
R413P Jennings et al.21
a The 18 mutations associated with an inconsistent phenotype
are shown. Mutations lacking a reported phenotype classification
( ; not shown in the table) are K42I, L52S, R53H, R68G,np 16
P69S, S70P, G103S, T124I, R157N, W187C, K274E, T278I, L293M,
G332V, S391I, and A447P. Phenotypes regarded as inconsistent
are those reported as very disparate for one mutation in the same
report or different reports. G46S is reported as “mild,” “severe-
mild,” or “severe”; L48S as “mild,” “moderate,” or “undefined”;
R158Q (a mutation traditionally defined as “severe”) as “severe,”
“mild-severe,” or “mild”; R243Q (another mutation traditionally
considered “severe”) as “severe” or “mild”; G218V as “severe” or
“unclassified”; R261Q as “moderate-severe,” “moderate,” or “mild-
severe.” The remaining 12 mutations have not been associated
with any specific phenotype (defined only as “unclassified”).
by which BH4 increases the stability of mutant PAH proteins in
vitro (thermal stability and protection against proteolytic deg-
radation and oxidative inactivation19,30) and also stabilizes PAH
WT and mutant proteins levels in cultured hepatoma cells and
mouse liver.48–50 Other mechanisms, such as the correction of a
high Km value for BH4, have also been shown to operate for a few
BH4-responsive mutants in vitro.
19,30,51 About 60% of patients with
BH4-responsive PKU show a mild phenotype and present muta-
tions that display significant residual activity in vitro.47
Results
Calculations in FoldX
One of the problems of modeling mutations within a rigid
backbone is the excessive penalization due to the contri-
butions of torsional and van der Waals forces. Thus, in
some cases, stability changes of 1500 kcal/mol are pre-
dicted, which are 150 times as large as the average stability
of a protein. A protein with such a destabilizing mutation
either will not fold or will undergo a local reorganization,
which is not easy to predict and model. As a result, when
correlations with the experimental data are performed,
these mutations will bias the analysis. This is because a
mutation predicted to destabilize the protein by 500 kcal/
mol will be as deleterious in a patient as one predicted to
be 20 kcal/mol, in that both of them will produce un-
folding or major reorganizations that will impair folding
and/or activity. Modeling such reorganizations is not
straightforward, and, to minimize this problem, we have
used an empirical approximation based on the capping of
the van der Waals clash between two atoms (before cor-
rection by solvent accessibility), using different ceilings:
5, 10, 15 (original capping value in FoldX), and 20 kcal/
mol. The underlying assumption was that, above a certain
value, the protein will either unfold or reorganize itself,
with a consequent decrease in stability and activity. Al-
though there is no evidence that local reorganization is
deleterious in general, especially when the reorganization
is small, conformational reorganization due to structural
relaxation of large van der Waals clashes is expected to
significantly affect protein conformation.52,53 In fact, this
assumption is validated when mutational effects on DDG
values at the different van der Waals ceilings are compared
with in vitro activities and patient phenotypes for PKU
mutations (see below and figs. 1–4).
Both small errors in structure determination and crystal
contacts could result in prediction errors. To minimize this
problem, we used various available crystal structures to
model the mutations—that is, two dimeric structural mod-
els from human PAH, residues 19–428 (based on the rat
structures PDB 1PHZ and 2PHM), which include the reg-
ulatory and catalytic domains and the dimerization motif,
and the tetrameric human structure, residues 111–452
(PDB 2PAH), which includes the catalytic and oligomeri-
zation domains. Eighty mutations were initially modeled
(table 1) (i) both in the dimeric and tetrameric structures
(60 mutations at the catalytic domain and dimerization
motif), (ii) only in the dimeric structures (19 mutations
at the N-terminal regulatory domain), and (iii) only in the
tetrameric model (one mutation at the tetramerization
motif, i.e., A447P). Mutations were divided into three dif-
ferent groups depending on their in vitro residual activity
(table 1). The predicted DDG values are shown in table 5,
and the relationship between residual activity and DDG
(in kcal/mol), calculated on the structure of the dephos-
phorylated dimeric form for 79 individual mutations
(A447P is not included in this structure), is represented in
figure 1A. Correlations obtained with the other structural
models are shown in figure 2A. The results show that the
structural model chosen for the FoldX analysis does not
significantly affect the overall outcome for the different
groups (notably, when a 5-kcal/mol energy penalty is
used) (fig. 2A). Moreover, if higher energetic penalties are
used, all three models provide similar mean DDG values
and dependencies on the energetic penalty for the differ-
ent activity groups (fig. 2C), except for a larger slope in
type III for the tetrameric structure. This appears to be the
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Table 4. Predicted Effect on DDG and Phenotypic Prediction based on FoldX
Analysis for 34 Missense Mutations Found in Patients with BH4-Responsive
PKU
Mutationa
Energetic Penalty
(kcal/mol) Linear Fitting
20 15 10 5
y0
(kcal/mol) m
BH4 responsive ( ):np 16
F55L 4.2 3.3 3.3 3.3 2.9 .05
S110L 7.4 6.2 5.1 3.5 2.4 .25
P119S 5.7 5.7 5.7 5.7 5.7 !.01
D129G 11.6 10.9 10.9 10.9 10.6 .04
A132V 21.2 18.5 11.0 7.9 2.8 .95
V177M 2.8 2.3 2.3 2.3 2.1 .03
V190A 2.3 2.3 2.3 2.3 2.3 !.01
P275L 23.6 20.7 17.8 14.3 11.4 .62
A300S .5 .5 .5 .5 .5 !.01
S310Y 157 126 92.3 56.4 24.1 6.71
A313T 29 22 16 8.2 1.2 1.39
P314S 7.6 7.6 7.6 7.6 7.6 !.01
K320N 1.8 1.8 1.8 1.8 1.8 !.01
A373T 19 16 13 9.8 6.8 .61
P407S 3.7 3.7 3.7 3.7 3.7 !.01
Y417H 7.3 7.1 7.1 7.2 7.2 !.01
Potentially BH4 responsive ( ):np 18
F39L 11 11 11 11 11 !.01
L48S 5.9 5.9 5.9 5.9 5.9 !.01
I65T 10 9.3 8.4 7.5 6.7 .17
R68S 6.3 6.3 6.3 6.3 6.3 !.01
A104D 7.4 6.9 6.3 5.7 5.1 .11
P211T 5.1 5.1 5.1 5.1 5.1 !.01
R241C 4.4 4.4 4.4 4.4 4.4 !.01
R241H 6.4 6.4 6.4 6.4 6.4 !.01
V245A 4.4 4.4 4.4 4.4 4.4 !.01
R261Q 7.4 7.4 7.4 7.4 7.4 !.01
I306V 2.6 2.6 2.6 2.6 2.6 !.01
V388M 1.7 1.7 1.7 1.7 1.7 !.01
E390G 1.1 1.1 1.1 1.1 1.1 !.01
A395P 48 38 27 14 3.5 2.26
A403V 15 12 9.8 7.3 4.7 .51
R408Q 9.5 9.5 9.5 9.5 9.5 !.01
Y414C 6.0 6.0 6.0 6.0 6.0 !.01
D415N 7.5 7.5 7.5 7.4 7.4 !.01
NOTE.—All calculations were performed on the unphosphorylated dimeric structure (PDB
2PHM).
a See the work of Blau et al.47 and the BIOPKU database for classification of mutations. In
brief, BH4-responsive mutations are found in patients with BH4-responsive PKU who are func-
tional hemizygous; potentially BH4-responsive mutations are found in responsive patients
(typically compound heterozygous) and display residual PAH activity in in vitro expression
analysis.
result of a large overdestabilizing effect for some muta-
tions at the 20-kcal/mol penalty with this structure, com-
pared with the dimeric structural models. The large SDs
observed in these plots (fig. 2C), especially at increasing
energetic penalties, are the consequence of differences in
the slopes of these dependencies for individual mutations
within each group (see table 6). At an energetic penalty
of 20 kcal/mol, DDG values (meanSD) for types I, II, and
III were calculated to be 5.45.0 kcal/mol, 12.315.1
kcal/mol, and 32.441.8 kcal/mol, respectively, whereas,
at a 5-kcal/mol penalty, the corresponding values were
4.32.8 kcal/mol, 5.74.8 kcal/mol, and 14.211.7 kcal/
mol, respectively.
It was interesting to note that, as well as the activity
groups, each individual mutation displayed a linear de-
pendence of DDG on the magnitude of the energetic pen-
alty applied (5–20 kcal/mol) (table 5 and fig. 2C; further
highlighted in fig. 3A for the unphosphorylated dimeric
model). A linear fitting of these data provides m (slope)
and y0 (intercept) values as fitting parameters (compiled
in table 5). The m values reflect the intrinsic dependence
of DDG on energetic penalties (i.e., the extra energetic pe-
www.ajhg.org The American Journal of Human Genetics Volume 81 November 2007 1013
Figure 1. Mutation-dependent destabilization and in vitro re-
sidual activity. A, Plot of calculated DDG (in kcal/mol dimer, at a
penalty of 5 kcal/mol) versus in vitro residual activity calculated
for the structure of the dephosphorylated dimeric form for 79
individual mutations (all compiled in table 1 except A447P, which
is not included in this structure). Seventy-four of these mutations
(unblackened triangles), grouped in types I, II, and III according
to the residual activities (table 1), were included in the calculation
of the meanSD DDG values (blackened circles) for types I, II,
and III (4.32.8 kcal/mol, 5.74.8 kcal/mol, and 14.211.7
kcal/mol, respectively). Five mutations were defined as outliers
(blackened triangles; R68G is also indicated by an arrow; also see
main text for details) and were not included in the calculation of
the mean DDG values. The line is only to guide the eye and has
no formal significance. B and C, MeansSDs of m and y0 values
for the different in vitro activity groups calculated using individual
fits for each mutation. P values are obtained from one-way ANOVA;
is considered statistically significant.P ! .05
nalization due to structural rearrangements caused by mu-
tation), whereas the y0 values appear to be associated with
the intrinsic penalization in the local environment of the
mutated residue. Thus, in spite of the large SD values
shown in figure 2A and 2C, calculation of the frequencies
of different m values shows that higher in vitro residual
activities are associated with lower m values and, to a lesser
extent, with lower y0 values (table 6).
Correlation between In Vitro Residual Activity and Energetic
Prediction by FoldX
As figure 1A shows, analysis of the mutation-associated
DDG values versus in vitro activity is not straightforward
because of the high degree of scatter. However, and as
discussed above, if we consider the frequency distribution
of the m and y0 values for the individual mutations, as
well as the averaged m and y0 values determined for each
group (types I, II, and III), we see a negative correlation
between the in vitro activities of the mutations and the
values of these parameters (table 6 and fig. 1B and 1C).
Actually, in some cases, m and y0 values differ significantly
between milder groups (types I and II) and the severe
group (type III) (fig. 1). Mutations in residues identified
as catalytic were considered outliers (blackened triangles
in fig. 1A) and were excluded from the calculation of the
mean values and the classification into activity groups.
These outliers were Y277D9 (affecting hydrogen bonding
to substrate), R270S54,55 (affecting hydrogen bonding/elec-
trostatic network at the active site and electrostatic bridge
to the substrate), and R158Q and E280K9 (strongly affect-
ing specific activity and reaction coupling).56
An additional outlier is R68G (shown in fig. 1A), since
the predicted effect on protein stability ( kcal/DDGp 8.7
mol) is abnormally high with respect to its very high in
vitro residual activity (table 1) and mild folding effect.57
Arg68 is located at the subunit interface in the dimer,58
and a high DDG value for the R68G mutant appears to be
partly explained by a relatively high contribution of the
subunit binding energy to the change in stability (see the
“Effects of Subunit Binding Energies in Oligomer Stability”
subsection). Other mutations for which inconsistencies
are encountered using different models are marked in ta-
ble 5. The different energetic values can be explained by
local differences in the structure due to crystal packing or
by small errors in structure determination arising from
ambiguities in the electron density, due to the different
resolution of the crystal structures used (i.e., 2.1 A˚, 2.6 A˚,
and 3.1 A˚ for the phosphorylated and unphosphorylated
dimeric forms and the tetrameric form, respectively).
There is no objective way of choosing one of the three
structural models to individually analyze the mutations,
although the resolution of the structures points to the
phosphorylated dimeric form as the best structure with
which to investigate the energetic effect of the mutations.
Moreover, the large number of mutations present at the
regulatory domain and which could not be analyzed in
the truncated tetrameric domain also supports the selec-
tion of this dimeric structure to run the prediction of the
phenotype (see below) in all missense mutations, notably
after determination that the overall conclusions and the
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Figure 2. DDG values (in kcal/mol dimer) predicted by FoldX with the use of different structural models. Data were obtained from
table 5 for the unphosphorylated dimer (based on PDB 2PHM; 74 mutations) (blackened circles), phosphorylated dimer (based on PDB
1PHZ; 74 mutations) (unblackened circles), and the N-terminal truncated tetramer (2PAH; 55 mutations) (blackened triangles). A, Plot
of DDG versus in vitro residual activity (types I, II, and II as defined in table 1) (with penalty of 5 kcal/mol). B, Plot of DDG (with
penalty of 5 kcal/mol) for PKU mutations classified by phenotypic association found in patients with PKU (as defined in table 2). C
and D, Dependence of DDG on different energetic penalties for PKU mutations classified by in vitro activity (C) or association with in
vivo phenotypes (D).
criteria for prediction of these analysis are not dependent
on the structural model selected (fig. 2).
Effects of Subunit Binding Energies in Oligomer Stability
The contribution of subunit binding energies within the
dimeric structure (monomer-monomer interactions) was
also calculated. Only 6 mutations (L48S, 1.25 kcal/mol;
R68G, 2.36 kcal/mol; R68S, 3.44 kcal/mol; P69S, 4.48 kcal/
mol; Y414C, 5.79 kcal/mol; and D415N, 4.85 kcal/mol)
of the 79 studied in this structural model, all located at
subunit interfaces, show a contribution 11 kcal/mol (en-
ergetic penalty 5 kcal/mol), indicating that the most fre-
quent and largest effects on stability arise from destabi-
lization of the PAH monomer. This is in agreement with
a lower abundance of damaging mutations at the dimer
or tetramer interfaces, as also shown in previous structural
analyses,20,21 suggesting that there is a higher degree of
flexibility in these regions than within the monomers.
Removal of these subunit binding energies from the FoldX
analysis does not significantly modify the overall results—
that is, the averaged values varied from 4.32.8 kcal/mol
to 3.62.5 kcal/mol for type I, from 5.74.8 kcal/mol to
5.33.3 kcal/mol for type II, and from 14.211.7 kcal/
mol to 14.111.2 kcal/mol for type III. However, in some
individual cases, the contribution from binding energies
is substantial (21% and 27.1% of the total DDG for L48S
and R68G, respectively) or predominant (54.6%, 65.5%,
82.9%, and 96.5% of the total DDG for R68S, D415N, P69S,
and Y414C, respectively). In those cases, and notably for
the outliers R68G and D415N, subtraction of the binding
energy results in DDG values that correspond better to in
vitro residual activity for the mutant. Thus, in spite of the
minor contribution of subunit binding energies to the pre-
dicted effects of PKU mutations on PAH stability in gen-
eral, detailed predictions for individual mutations should
include evaluations of these binding energies.
Protein Misfolding and Aggregation
The observed correlation between in vitro residual activity
and energetic prediction by FoldX indicates that the de-
stabilization produced by the mutations appears to be the
major cause of the reduced in vitro residual activity, as
indeed pointed out in reports of previous structural20,21
and expression6,8,9,59 studies. Protein destabilization could
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Figure 3. Effect of the energetic penalizations applied (5–20
kcal/mol) on the DDG values calculated for the unphosphorylated
dimeric model (based on PDB 2PHM). A, Seventy-four PKU mu-
tations classified into three mutant types according to their in
vitro residual activity (as defined in table 1). Lines are linear fits
as follows: type I (blackened triangles), kcal/mol,y p 3.9 0.10
; type II (unblackened circles),mp 0.07 0.01 y p 3.6 0.10
kcal/mol, ; type III (blackened circles),mp 0.44 0.01 y p0
kcal/mol, . B, Forty-one PKU muta-8.4 0.4 mp 1.21 0.03
tions classified into three phenotypic groups according to their
associated patient phenotypes (as defined in table 2). Lines are
linear fits as follows: severe PKU (blackened triangles), y p0
kcal/mol, ; mild PKU (unblackened cir-7.2 0.5 mp 1.19 0.04
cles), kcal/mol, ; and MHP (black-y p 4.8 0.1 mp 0.19 0.010
ened circles), kcal/mol, .y p 2.6 0.1 mp 0.00 0.010
Figure 4. Mutation-dependent destabilization and in vivo pa-
tient phenotype. A, Calculated effect on DDG (in kcal/mol dimer)
for 46 PKU mutants classified by phenotypic groups at a 5-kcal/
mol penalty. The meanSD DDG values (blackened circles) for the
three phenotypic groups, calculated using 41 mutations (unblack-
ened triangles), were 2.82.2 kcal/mol, 5.72.7 kcal/mol, and
13.09.5 kcal/mol for MHP (group 1), mild (group 2), and severe
(group 3) phenotypes, respectively. Five outliers (blackened tri-
angles) have been removed (see text for details) for the calculation
of the mean values. B and C, MeansSDs of m and y0 values for
the different phenotypic groups, calculated using individual fits
for each mutation. P values are obtained from one-way ANOVA;
is considered statistically significant.P ! .05
lead to unfolding and, in turn, to either degradation or
precipitation due to the exposure to the solvent of aggre-
gation-prone regions. It is also possible that some muta-
tions could produce an increase in aggregation tendency,
thus exacerbating the destabilizing effect. We therefore
checked the effect of the mutations on the aggregation
tendency of the protein, using the sequence-based TANGO
analysis,60 in spite of the fact that increased degradation,
rather than massive aggregation, of the PKU mutants has
been suggested as the molecular loss-of-function mecha-
nism in vivo.4,14 It was particularly relevant to investigate
the effect for mutations showing DDG values that are
highly dependent on the structural model employed
(table 5). Only in some cases we did see a significant in-
crease in the aggregation tendency per residue in the mu-
tated sequence (i.e., WT aggregation tendency of 2.9% per
residue compared with 3.3% in the case of G247V [data
not shown]). Protein destabilization thus appears to be
the major determinant of the in vitro residual activity
observed.
Correlation between In Vivo Metabolic Phenotypes
and Energetic Prediction by FoldX
More interesting than the correlations between predicted
DDG values for the mutations and in vitro residual activity
is the comparison of the predicted changes in PAH stability
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Table 5. Effects on DDG Caused by
Mutation, Evaluated Using Four Different
Energetic Penalizations in Three Different
Structural Models
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
with the mutation-associated phenotype in patients. Table
2 includes the mutations from table 1 for which “consis-
tent” mutation-associated phenotypes are found in the
literature (according to the criteria described in the “Data
and Methods” section). The results of this correlation with
use of the dimeric unphosphorylated model are shown in
figure 4A, although similar results are obtained if other
structural models are used for the correlation (fig. 2B and
2D). Of 46 individual mutations (table 2), 41 were used
to calculate the mean DDG for the three in vivo pheno-
typic groups. Five outliers were not included in the cal-
culation of the average values: two mutations in the MHP
group (A47V and D415N) and one in the mild group
(P122Q), which display abnormally high energetic pen-
alties, and two in the severe group (Y277D, DDGp 1.9
kcal/mol, and E280K, kcal/mol), which areDDGp0.3
catalytic (see above).
Milder phenotypes have a lower energetic impact on
PAH stability ( ) (fig. 4A). The errorsMHP ! mild ! severe
associated with each group in this plot are lower than
those observed for the correlations of DDG with the resid-
ual activity (fig. 1A). This is most probably because the
phenotyping process is more strict (i.e., more care is taken
to phenotypically classify a patient-associated mutation)
and because the classification is based on a large number
of patients, whereas some residual activities have been
measured in only one report or have been reported as
discrepant residual activities by different reports (there-
fore, activities intrinsically carry a higher level of noise).
It has been documented that genotypes correlate with
metabolic phenotype (L-Phe tolerance), whereas in vitro
residual activities frequently do not.3 The high frequency
of “null” mutations (predicted to abolish activity) makes
“functional hemizygosity” a frequent event, allowing us
to phenotypically classify many mutations not found in
homozygosity.3,32 In vitro expression analysis has, in fact,
been a powerful tool for the study of pathogenic mech-
anisms in PKU and for the rank-ordering of the severity
of each mutation. However, different experimental pro-
tocols in the transient expression and in activity mea-
surements may contribute to the scatter found in the ex-
perimental data.10
The frequency distributions of m and y0 values also differ
more among phenotypic groups than among the classi-
fications based on in vitro activities (table 6). Significantly
lower m values are associated with milder phenotypes
( ) (fig. 4B), whereas y0 values of mildersevere 1 mild 1 MHP
groups (mild or MHP) are also significantly lower than
those for severe phenotypes ( ) (fig.MHP ≈mild ! severe
4C). Interestingly, m and y0 values estimated both from
the activity (fig. 1B and 1C) and from the phenotypic
classification (fig. 4B and 4C) are relatively similar. These
results indicate that FoldX analysis is capable of correlat-
ing mutational effects on stability with both high in vitro
activities and mild in vivo phenotypes (low m and y0 val-
ues), whereas mutations that display low activities are
linked to severe phenotypes (high m and/or y0 values).
Phenotypic Prediction
The correlations obtained between energetic penalties and
the predicted DDG values (table 6 and fig. 4) suggest that
both fitting parameters y0 and m might be simple tools to
provide guides for predicting an in vivo phenotype and,
to a lesser extent, for in vitro residual activity associated
with a certain PKU mutation, as follows: (a) MHP phe-
notypes, –0.1 and kcal/mol (associated withmp 0 y  30
in vitro residual activities 150% of WT); (b) mild pheno-
types, –0.3 and –7 kcal/mol (associated withmp 0.1 y p 30
in vitro activities ∼10%–50% of WT); and (c) severe phe-
notypes, and kcal/mol (associated with lowm 1 0.3 y 1 70
activity, 10% of WT). As we pointed out above, m values
reflect the extra energetic penalization due to structural
rearrangements caused by mutation, whereas y0 values
are the intrinsic penalization in the local environment of
the mutated residue. We therefore treated y0 values as a
first prediction of the phenotype associated with a certain
mutation, whereas m values are consequently considered
when they predict a more severe phenotype (consider, e.g.,
mutations such as S349P, which is associated with patients
with severe phenotypes and which displays kcal/y p 3.00
mol but a very large m value [1.6]; certainly, in cases like
this, m values must dominate in the final prediction).
We then calculated the energetic impact (DDG, m, and
y0 values) and the predicted phenotype for 238 missense
mutations for which in vitro residual activity has not been
reported—mostly because these mutations are rare—and
the results are summarized in table 7. With use of these
criteria, 32.6%, 26.4%, and 41.0% of the 238 missense
mutations predicted by FoldX are associated with MHP,
mild, and severe phenotypes, respectively.
Validation of FoldX-Based Prediction of Metabolic
Phenotypes
First, we cross-validated the predictive power of FoldX for
the mutation associated with in vivo phenotypes, by test-
ing our m and y0 predictive guidelines on the mutants for
which phenotypic classification has been reported (re-
ferred to as the “training data set”) (tables 2 and 7) and
which were actually used to calculate the cutoff values for
m and y0 parameters for the various phenotypic groups’
criteria (fig. 4) (see also the “Phenotypic Prediction” sub-
section). Of the MHP mutations, 54.5% were predicted to
be associated with the MHP phenotype, whereas the re-
maining 45.5% were predicted to be associated with mild
PKU phenotypes. In the mild PKU phenotype group,
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50.0%, 16.7%, and 33.3% were predicted to be associated
with mild, MHP, and severe PKU phenotypes, respectively,
whereas 77.8% of the severe mutations were correctly pre-
dicted as severe PKU (the remaining 22.2% were predicted
as mild PKU). Thus, although there is some degree of un-
certainty, we are able to conclude that our FoldX-based
analysis is a satisfactory tool that can correctly predict a
significant fraction of the phenotypes associated with PKU
mutations. Uncertainty may be related to different factors,
such as imprecision in the energy calculation by FoldX or
errors in the structural models used, interindividual phe-
notypic variability of some mutations, and differences in
potential modifiers of the metabolic outcome.15 Moreover,
there is no absolute consensus in the international guide-
lines for phenotypic classification.3
Further cross-validation was attempted by analyzing
the correlation of the predicted PKU phenotype associated
with some of the 238 mutations for which in vitro residual
activity has not been reported (i.e., the predicted data set)
(table 7). For 38 of these mutations, we have found as-
sociations with a certain phenotype in the literature
(shown in table 7). All the mutations reported as MHP
mutations ( ) were correctly predicted by our FoldXnp 7
approach. However, the predictive power of FoldX was
significantly lower in the mild and severe PKU groups.
Structural analysis shows that, for nine mutations (eight
in the severe PKU group and one in the mild PKU group)
for which severity in metabolic phenotype is underesti-
mated by FoldX analysis, the mutation likely affects PAH
catalytic properties. The R158W mutation is expected to
affect catalytic efficiency and coupling, as described for
the R158Q mutant.56 The H285Y mutation would directly
affect iron coordination, as described for the H285S mu-
tant.65 I269N and R270K are expected to distort important
ionic interactions toward L-Phe at the substrate binding
site.66 F331C and F327L are located at the substrate and
cofactor binding sites, respectively, where they likely affect
proper L-Phe and BH4 binding. D145V, P275R, and G352R
are located at the entrance of the L-Phe binding site, and
these mutations might also affect proper substrate bind-
ing. If these mutations are withdrawn from the predicted
data set, FoldX prediction is improved in the severe group
(from 39.1% to 60% correct prediction of severe PKU phe-
notypes) but not so much in the mild group (from 25.0%
to 29.1%). A possible explanation of the higher prediction
success for the mutations in the training data set is that
they are among the most frequent PKU mutations, and
genotype-phenotype correlations have been reported by
different groups that used several patients for each mu-
tation. In the predicted data set, often only one report or
even one patient is reported (table 7); therefore, genotype-
phenotype correlations based on patient phenotypes are
not so robust. For the rest of the ∼200 mutations in the
predicted data set, little or no information about homo-
zygotic or functional hemizygotic patients is found in the
PAHdb or BIOPKU databases; thus, no reliable clinical phe-
notype can be assigned and compared with the FoldX-
predicted phenotypes.
BH4-Responsive Mutants
BH4-responsive HPA/PKU is a PKU subtype that has re-
cently been put forward to designate the disease in a sub-
group of patients who respond to supplementation with
high doses of the natural cofactor BH4 (130% L-Phe re-
duction in plasma within 24 h after BH4 administra-
tion).47,67 These patients carry specific mutations in the
PAH gene leading to either single amino acid alterations
or small inframe insertions or deletions. Table 4 shows
DDG values estimated for missense mutations detected in
BH4-responsiveness studies in patients with PKU. Muta-
tions have been divided into two groups (BH4-responsive
and BH4–potentially responsive mutations) on the basis
of previously established criteria.47 Both groups cluster
around similar mean y0 values (5.75.9 kcal/mol and
5.52.5 kcal/mol for BH4-responsive and BH4–potentially
responsive groups, respectively; ), whereas m val-Pp .88
ues are not significantly different either (mp 0.66
and 0.170.54 for BH4-responsive and BH4–poten-1.67
tially responsive groups, respectively; ). Pheno-Pp .23
typic predictions of mutations of both groups revealed
that a large fraction of mutations are predicted to be as-
sociated with mild phenotypes (31.2% and 16.7% of MHP
and 18.7% and 50% of mild for BH4-responsive and BH4–
potentially responsive groups, respectively). These predic-
tions are consistent with clinical studies and biochemical
analyses of BH4 responsiveness, which have shown that
most (∼60%) of the patients47 who responded to BH4 have
mild phenotypes and carry at least one mutant allele with
relatively high in vitro residual activity (130% of WT
activity19,30,47). Our results thus suggest that one of the
main molecular mechanisms underlying BH4 responsive-
ness is BH4-induced stabilization of PAH mutants with
mild stability defects, as we have proposed elsewhere on
the basis of in vitro expression analysis19 and in vivo stud-
ies.48 BH4 thus can be added to the list of chemical and
pharmacological chaperones that emerge as potential
therapeutic agents for correction of protein destabilization
and misfolding.13,68,69
Hotspots for Destabilization
Previous attempts to predict the frequency of HPA/PKU
mutations on the basis of the occurrence of CpG dinu-
cleotides have shown that the predictions do not correlate
with the actual occurrence of mutations among the pop-
ulation.20 All the PAH mutations encountered so far are,
in fact, spread all over the three-dimensional structure of
PAH.20 Figure 5 shows the location of all mutations com-
piled in table 7, as represented on the composite full-
length subunit structure24 according to the final pheno-
typic prediction (fig. 5A), the y0 parameter (fig. 5B), and
the m parameter (fig. 5C). We can see that most of the
mutations that impair PAH stability affect residues that
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Table 6. Frequency Distribution and Mean Values of the m and y0 Parameters Determined from the
Linear Fitting of DDG versus Energetic Penalizations
PKU Mutation
Classification
m y0
Frequency
MeanSD
Frequency
MeanSD
(kcal/mol)m ! .1 .1 ! m  .3 m 1 .3 y  30 3 ! y  70 y 1 70
Activitya (% of WT):
Type I: 50% .889 0 .111 .07.20 .333 .500 .167 4.002.50
Type II: 10%–50% .516 .194 .290 .44.75 .452 .419 .129 3.643.40
Type III: !10% .417 .083 .500 1.182.05 .042 .291 .667 8.283.88
Phenotypeb:
Group 1: MHP 1 0 0 0 .556 .444 0 2.711.44
Group 2: mild PKU .177 .411 .411 .15.25 .25 .417 .083 4.722.71
Group 3: severe PKU .333 .056 .611 1.191.14 .167 .444 .389 7.165.04
a Seventy-four mutations, classified by in vitro activity, from table 1 after withdrawal of five outliers and A447P.
b Forty-one mutations, classified by in vivo phenotypes, from table 2 after withdrawal of five outliers.
Table 7. Phenotypic Prediction Based on
the Calculation of the Energetic Impact
(DDG) for 318 PKU Missense Mutations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
are partly or totally buried, as also inferred from previous
structural interpretations of the effect of PKU muta-
tions,20,21 whereas surface mutations have little effect on
stability, especially when they are in loops (fig. 5). The
most destabilizing mutations are those that introduce
large van der Waals clashes in a buried position (by in-
creasing the volume of the side chain because of muta-
tion), which would either prevent protein folding or in-
duce large conformational rearrangements (therefore
displaying large m values) (fig. 5C). Such mutations will
be predicted to be associated with severe phenotypes ac-
cording to the criteria elaborated in this work (fig. 5A; see
above and table 7 for criteria). Our results suggest that
PAH structure and stability are highly optimized in terms
of atomic packing and are very sensitive to mutations that
increase side-chain size (table 7).
The frequency distribution of the predicted phenotypes
(including all mutations in table 7) along the PAH amino
acid sequence is rather similar in segments 1–225 and
331–452 (MHP, 33.8%–35.9%; mild, 22.5%–38.3%; severe,
27.7%–43.7%). However, in the 226–330 region, there is
a high predominance of predicted severe phenotypes
(MHP, 21.7%; mild, 27.0%; severe, 51.3%) (table 7 and fig.
5). This segment largely comprises exons 7–9 in the PAH
protein and covers most of the catalytic site. Expression
analyses have demonstrated elsewhere a serious destabi-
lizing effect of recurrent exon 7 (residues 235–281) mu-
tations.6 In fact, however, the highest frequency of mu-
tations predicted as severe (70.4%) is found in exons 8–9
(residues 282–323), which appear to contribute strongly
to PAH stability by preserving the arrangement of the iron-
coordinating residues (fig. 6). An important role in main-
taining PAH native-state stability can thus be assigned to
the region of residues 226–330 (highlighted in fig. 6), be-
yond their possible roles in catalysis (some of these resi-
dues also have a proven catalytic function—i.e., R270S,
Y277D, and E280K). Other residues that are regarded as
playing an important structural role are those involved in
interdomain interactions in a monomer, such as Ser70–
Arg71, P122, Leu308–L311, and Arg40820 (fig. 6). Muta-
tions at most of these residues are also predicted to be
severe and, in many cases, display large m values (table
7).
Discussion
The current view of protein folding describes folding re-
actions as complex processes in which a polypeptide
reaches its native structure by searching the conforma-
tional space through a multidimensional energy surface,
or “energy landscape.”70 During a folding reaction, the
polypeptide chain may populate intermediate states to as-
sist the protein to find the native folded state, even though
these intermediates might also act as “kinetic traps” and
be more prone to misfolding.70 Missense mutations often
result in an increased tendency of the newly synthesized
protein to misfold, leading to reduced in vivo function.71
In addition, misfolded proteins may be deleterious to cells
per se, since they may interact with other misfolded pro-
teins, resulting in toxic intracellular aggregation that can
interfere with normal cellular function.70,72 The cell limits
the accumulation of misfolded conformations by using a
protein quality control (mainly in the cytosol and endo-
plasmic reticulum) that involves folding assistance by
chaperones.73 The protective mechanisms also include
elimination of the defective proteins via degradation
through the polyubiquitin-dependent proteasome path-
ways or other protein quality-control proteolytic sys-
tems.10,13,74,75 Protein misfolding seems to be an intrinsic
property of the folding process of large and complex pro-
teins, and as many as 30% of the newly synthesized pol-
ypeptides in eukaryotes may be rapidly degraded after syn-
thesis.74 Despite stringent quality-control mechanisms,
mutations that affect protein folding cause a wide range
of diseases, both rare and common. Among mutation-in-
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Figure 5. Mutation-dependent destabilization represented on
the dimeric structure (PDB 2PHM). All mutations summarized in
table 7 have been represented according to the following criteria.
Mutated residues are colored according to (A) the predicted phe-
notype: MHP (blue), mild (yellow), and severe (red); (B) the y0
parameter: kcal/mol (blue), kcal/mol (yellow),y  3 3 ! y  70 0
and kcal/mol (red); and (C) the m parameter: (blue),y 1 7 m 0.10
(yellow), and (red). For the cases with sev-0.1 ! m 0.3 m 1 0.3
eral mutations in the same residue, that position has been colored
according to the mutation with the most severe effect.
duced misfolding diseases, PKU (caused by mutations in
PAH) is considered a paradigm of misfolding metabolic
diseases.11,76 Several reports have substantiated PAH mis-
folding due to mutation, as shown by increased proteo-
lytic turnover with expression in reticulocyte cell-free sys-
tems and mammalian cells and by modulation of PAH
mutant residual activity and protein levels with chape-
ronin coexpression in E. coli.7,9,19,30,59
Prediction of the misfolding properties of PAH mutants
is not straightforward, since it would depend on knowl-
edge of the kinetic partitioning of the protein between
native, partially folded, and misfolded states.73 Some ap-
proaches based, for instance, on molecular-dynamics
simulations of the kinetic competition between folding
and misfolding have been shown to be useful for the study
of the basic principles of misfolding, but they are limited
to simulations of small and simple proteins or model
homopolymers.77,78
Alternatively, the effect of misfolding mutations can be
considered from the effect of the stability on the folded
protein, which would be related to reductions in the half-
life or steady-state protein levels in vivo. It has been shown
that mutation-dependent destabilization may decrease
mutant protein levels by reducing thermodynamic and/
or kinetic stability of proteins associated with different
misfolding disorders, such as amyotrophic lateral sclerosis,
cancer, and familial and systemic amyloidosis.79–85 The de-
stabilizing mutational effect on the native-state stability
may reduce protein thermodynamic, as well as kinetic,
stabilities, which can be translated into increased aggre-
gation or degradation rates in vivo.86 Thus, an approach
based on the prediction of PKU phenotype from muta-
tional effects on native-state stability seems plausible, and
it is supported by the fact that thermal denaturation ex-
periments have shown lower stability in most of the PKU
mutants studied in vitro so far,7,9 indicating mutational
effects on the PAH native-state stability. Different com-
putational approaches have indeed been successfully ap-
plied (mainly in small model proteins) to predict the ef-
fects on thermodynamic stability caused by mutation.
These predictive achievements are in fact remarkable,
since development of these force fields to predict muta-
tion-dependent destabilization is a difficult task because
DG values are small numbers resulting from the almost
complete cancellation of large different (enthalpic and en-
tropic) contributions.87 Several of these computational ap-
proaches have provided good correlations between pro-
tein destabilization, as measured in vitro and as predicted
in silico in studies involving large sets of mutants.88–92
These and other similar approaches have been applied, to
test whether disease-related missense destabilizing muta-
tions can actually be discriminated from neutral poly-
morphisms.93–96 However, to our knowledge, no theoret-
ical approaches so far have provided strong evidence of
correlation between stability changes and phenotypic out-
come in large-scale studies for misfolding diseases related
to loss-of-function mechanisms.
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Figure 6. Hotspots for destabilization. The modeled composite
subunit structure of human PAH is shown in ribbon representation,
with regions 235–281 corresponding to exon 7 (green) and regions
282–330 including exons 8 and 9 (orange). Some residues impor-
tant for interdomain interactions in the monomer (Ser70–Arg71,
P122, Leu308–L311, and Arg408) are shown in dark red. The non-
heme iron at the active site is shown as a yellow sphere, and the
coordinating residues His285, His290, and Glu330 are shown as
orange sticks. See the main text for details.
During the past several years, major advances have been
achieved for the structural-functional characterization of
PAH and the elucidation of genotype-phenotype relation-
ships in PKU. In vitro expression analyses have provided
strong evidence, for most of the PKU mutations, of mis-
folding effects on PAH protein, which may lead to in-
creased degradation rates in vivo.8–10,97 Elucidation of the
crystal structures of different truncated forms of human
and rat PAH16,18,55,98–101 have provided the structural frame-
work to qualitatively correlate mutational effects on struc-
ture and function, and, indeed, these structural analyses
agree well, in many cases, with results from in vitro ex-
pression studies and in vivo metabolic phenotypes.20–22,31
However, many PKU mutations are rare; therefore, ge-
notype-phenotype correlations cannot be assessed from
patients’ data. Moreover, expressing all the missense mu-
tant proteins would be a very time-consuming task. Our
approach based on energetic calculation of mutation-de-
pendent destabilization of PAH protein, which is based on
the PAH crystal structures available and the semiempirical
energy function FoldX, aims to help fill this gap in the
genotype-phenotype correlations in PKU, especially in the
case of rare and new mutations.
Conclusions
PKU is a paradigm of protein-misfolding diseases that are
caused by loss-of-function pathogenic mechanisms,4,10,11,
14 for which the screening and genotyping of neonatal
infants during the past few decades have enabled us to
identify patients and to prevent the major problems
caused by disease. In this work, we have embarked on a
structure-based energetic prediction of the impact of PKU
mutations on PAH native-state stability. This approach has
made it possible to capture and confirm the main path-
ogenic mechanism underlying PKU: the larger the DDG or
structural effect on PAH native state, the lower the activity
in vitro and the more severe the phenotype. In vivo met-
abolic phenotypes have been shown to be better predicted
by FoldX analysis than are in vitro residual activities, prob-
ably because of a higher stringency in the phenotyping
process and because of the large number of patients who
carry these frequent mutations. Additional analyses per-
formed using the TANGO algorithm60 for PKU mutations
have shown negligible contributions to misfolding from
a greater propensity to aggregation, compared with the
destabilization predicted by FoldX, which agrees well with
the absence of reports of amyloidosis in patients with PKU.
Moreover, PKU has been classified as a “complex trait”
genetic disease, in which the phenotypic outcome in in-
dividual patients can be significantly modulated by other
genetic and nongenetic modifying factors that can con-
tribute to the metabolic and cognitive phenotypes and
that would make a genotype-phenotype correlation diffi-
cult.15,102 A degree of variability in PAH residual activity
associated with a given mutation (or mutations) has oc-
casionally been invoked to explain inconsistencies in ge-
notype-phenotype correlations; these variations are jus-
tified by, among other mechanisms, individual differences
in potential modifiers, like intestinal absorption and trans-
port of L-Phe, folding machinery, or intracellular levels of
BH4 and L-Phe, which affect the residual activity and sta-
bility of the mutant proteins.4,9,15,19 The predictive power
of FoldX, however, recognizes the classical “monogenic”
autosomal recessive factor (protein destabilization caused
by mutation of the PAH protein) as the major determinant
for this outcome in most cases. Residues in exons 7–9 and
in the interdomain regions within the subunit appear to
play a remarkable structural role, constituting hotspots for
the destabilization of PAH (fig. 6).
Our results show a positive prediction for a testing data
set that is representative of a large fraction of mutant phe-
notypes in vivo, and we consider that this procedure will
be useful to predict the phenotype associated with other
rare or new mutations detected in patients with PKU (as
performed for the 238 missense mutations for which no
in vitro expression analysis is available) (table 7). However,
additional factors must be considered that may contribute
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to the patients’ phenotypes, such as possible effects on
catalysis and the fact that the PAH mutant genotype is
the main, but not the only, determinant of the metabolic
phenotype. Our approach, which is based on correlations
between mutational effects on protein unfolding ener-
getics and metabolic phenotypes (with use of the m and
y0 parameters as guides), thus appears as an alternative, or
at least as an aid, to current methods of performing or
predicting genotype-phenotype correlations based on the
determination of in vitro residual activities associated with
these mutations (table 1). As a consequence, a predictive
guideline associating the actual PKU mutation with in vi-
tro residual activities and metabolic phenotypes, on the
basis of the application of different energy penalties in the
FoldX calculations, emerges as a result of this work. The
FoldX Web server will be modified to automatically predict
the phenotypic effects of single amino acid mutations.
The use of protein-design algorithms to model any mu-
tation and to predict the phenotypic effect (except for
mutations involving the active site, which affect catalysis
with or without affecting protein stability) can be ex-
tended to other misfolding diseases for which a loss-of-
function mechanism has been described, as long as an
adequate three-dimensional structure is available. This
predictive tool contributes to the translational concept of
from protein energetics to clinical phenotype.
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Web Resources
The URLs for data presented herein are as follows:
FoldX Web server, http://foldx.embl.de
International Database of BH4-responsive HPA/PKU (BIOPKU),
http://www.bh4.org/biopku.html
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for PKU)
PAHdb, http://www.pahdb.mcgill.ca/
PDB, http://www.rcsb.org/pdb/ (for 1PHZ, 2PHM, and 2PAH)
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